HANGZHOU, China, Sept. 30, 2024 /PRNewswire/ — Zhejiang Doer Biologics Co., Ltd. (“Doer Bio”) has announced the successful dosing of the first patient in its Phase 2 clinical trial of DR10624. This innovative treatment targets severe hypertriglyceridemia (SHTG) and is a first-in-class tri-specific agonist that activates the Fibroblast Growth Factor 21 receptor (FGF21R), Glucagon-like Peptide-1 receptor (GLP-1R), and Glucagon receptor (GCGR).
The Phase 2 study is designed as a randomized, placebo-controlled, double-blind trial to assess the efficacy and safety of three different doses of DR10624 in adult patients with SHTG. Eligible participants will have fasting triglyceride levels of at least 5.65 mmol/L (500 mg/dL). The study aims to enroll a total of 72 participants.
“DR10624 is a long-acting tri-agonist developed using our proprietary MultipleBody® platform technology,” said Yanshan Huang, Ph.D., founder and CEO of Doer Bio. “It has shown remarkable effectiveness in reducing body weight, lowering triglycerides, normalizing blood lipids, and improving liver function in non-clinical studies.”
Dr. Yongliang Fang, Chief Operating Officer of Doer Bio, expressed enthusiasm about the trial’s progress. “Patients with severe hypertriglyceridemia face a higher risk of acute pancreatitis and atherosclerotic cardiovascular disease,” he noted.
“This Phase 2 study will help us determine the optimal dose for future Phase 3 clinical trials. We are committed to advancing DR10624 as a potential treatment for those affected by SHTG.”
Doer Bio is focused on developing innovative biotherapeutics for metabolic diseases and cancers. The company aims to address unmet medical needs through its advanced research and development efforts.
Related topics:
- Significant Global Cardiovascular Risk Linked to High Lipoprotein(a) Levels
- Higher Glaucoma Risk Associated With Statin Use in Adults With Hyperlipidemia
- Gut Microbiome Disturbances & Glycerolipid Metabolism in High-Fat Diet-Induced Hyperlipidemia